News 24 Jun. 2021
Curtis successfully defends foreign states' procedural privileges in the UK Supreme Court
News 23 Jun. 2021
Ibrahim Elsadig joins Curtis as Partner in Dubai
News 09 Aug. 2021
Curtis, Mallet-Prevost, Colt & Mosle enters into association with Chevalier Law in Singapore.
Event 23 Apr. 2021
Partner Borzu Sabahi to speak on Damages, Enforcement and Annulment of Arbitral Awards at Executive Training Program hosted by the Government of India and the Indian Institute of Foreign Trade
Client Alert 18 Oct. 2021
Senior Associate Martin Wolff Discusses Practical Questions with Regard to the German Implementation of the EU Directive on Cross-Border Tax Arrangements (DAC6) in Institutional Money
News 18 Oct. 2021
Jan Krupski Joins Curtis as a Partner in Frankfurt
News 15 Oct. 2021
Claudia Frutos-Peterson and Elisa Botero Ranked Among the Top 100 Female Lawyers in Latin America by Latinvex
News 13 Oct. 2021
Curtis Joins The Appellate Project to Promote Appellate Practice to Diverse Law Students
Client Alert 15 Oct. 2021
Recent change in Dubai’s Arbitration Landscape.
News 20 Sep. 2021
Curtis Successfully Defends the Sultanate of Oman and Oman Aluminium Rolling Company LLC in U.S. Department of Commerce Trade Case
Client Alert 05 Oct. 2021
Proposed Legislative Changes to Federal Estate, Gift and Trust Taxation
Publications 22 Sep. 2021
Client Alert 24 Jun. 2021
U.S. Insight: Update on Virtual Notarization (Executive Order 202.7) During the COVID-19 (Coronavirus) Pandemic (Updated: June 24, 2021)
U.S. Insight: Update on Virtual Witnessing (New York Executive Order 202.14) During The COVID-19 (Coronavirus) Pandemic (Updated: June 24, 2021)
News 12 Oct. 2012
New York, October 11, 2012 — Curtis, Mallet-Prevost, Colt & Mosle LLP represented Bionomics Limited in the Australian biotechnology company's acquisition of San Diego-based Eclipse Therapeutics Inc.
The transaction was structured as a stock-for-stock reverse. Additional cash consideration may be payable post-closing upon the achievement of certain milestones.
Bionomics, as a result of the deal, will gain an important strategic base in the United States, the world's largest pharmaceutical market, with the acquisition. The addition of Eclipse will expand Bionomics' oncology pipeline and establish the company as a global leader at the forefront of cancer stem cell therapeutics.
Bionomics, based in Adelaide, is a leading international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, Alzheimer's disease, epilepsy and multiple sclerosis.
Eclipse Therapeutics is a private biotech company that was spun off from Biogen Idec Inc. Eclipse develops drug compounds that target cancer stem cells, the root cause of many cancers.
The Curtis team of attorneys was led by partner Lawrence Goodman and associates Douglas Glazer and Joshua Holt from the Corporate M&A group, partner Alan Berlin and counsel Kuang-Chu Chiang from the Tax group, and counsel Eric Stenshoel from the Intellectual Property practice.
The Curtis Mergers & Acquisition practice group focuses primarily on middle market M&A and private equity transactions across a broad range of industries. Curtis advises both private and public entities and financial sponsors in a broad range of transactional matters, counseling buyers, sellers and targets in connection with mergers, acquisitions, joint ventures, leveraged buy-outs, strategic alliances and other related transactions. The Curtis M&A group has extensive experience in complex cross-border transactions and foreign investments in the United States, Europe, Latin America, the Middle East and Asia.
Curtis, Mallet-Prevost, Colt & Mosle LLP is a leading international law firm providing a broad range of services to clients around the world. Curtis has 16 offices in the United States, Latin America, Europe, Central Asia, and the Middle East. The firm's international orientation has been a hallmark of its practice for nearly two centuries. For more information about Curtis, please visit www.curtis.com or follow Curtis on Twitter (twitter.com/curtislawfirm) and Facebook.com/Curtis.Careers).
Mergers and Acquisitions
Douglas Ian Glazer